Firebrick Pharma Share Price and Company Fundamentals
Last traded: Today at 2:05 AM
Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.
Key Metrics
PE ratio
-
PB ratio
9.29
Dividend yield
-
Beta
1.37
Market cap
$16.35M
Enterprise value
$13.79M
Company profile
| Industry / Sector | Drug Manufacturers - General / Healthcare |
|---|---|
| Website | https://firebrickpharma.com |
| Mailing address | 440 Collins Street Level 10 Melbourne VIC 3000 Australia |
| Phone / Fax | 61 1300 301 874 / |
Dividends
More: Firebrick Pharma Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Firebrick Pharma paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.FRE dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Firebrick Pharma.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Peter Laurence Molloy BSc, FAICD, MBA | Founder, Executive Chairman & CEO | 71 | |
| Dr. Stephen Francis Goodall MASc, MBA | Founder, COO & Executive Director | ||
| Mr. Kavi Bekarma B.Sc., C.A. | Chief Financial Officer | ||
| Dr. Simon Tucker | Chief Scientific Officer | ||
| Dr. Monique Baldwin | Head of Regulatory Affairs | ||
| Mr. Stephen Buckley | Company Secretary |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-364.13%
Return on assets
-74.97%
Return on equity
-143.50%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Firebrick Pharma is 16.35M and its enterprise value is 13.79M. The enterprise value to revenue ratio of FRE is 26.75. The enterprise value to EBITDA ratio of FRE is -5.45.
The FRE's stocks Beta value is 1.37 making it 37% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Firebrick Pharma (FRE)
Firebrick Pharma (ASX:FRE) Frequently Asked Questions
1. What is Firebrick Pharma's Stock Symbol?
Firebrick Pharma trades on ASX under the ticker symbol "FRE".
2. What is Firebrick Pharma's stock price today?
One share of FRE stock can currently be purchased for approximately $0.065.
3. How can I contact Firebrick Pharma?
Firebrick Pharma's mailing address is 440 Collins Street Level 10 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 1300 301 874.
4. What is Firebrick Pharma's official website?
The official website of Firebrick Pharma is https://firebrickpharma.com.